Suzanne M. Scheaffer

The paper investigates how IGHV3-53/3-66 antibodies from Omicron BA.1 infection neutralize emerging SARS-CoV-2 variants through structural and mutational analysis.

This study characterizes the antigenic properties of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal models and finds they are antigenically divergent from existing variants with lower homologous serum titers.

Booster SARS-CoV-2 mRNA vaccine recruits and broadens GC B cell responses targeting a highly conserved site on receptor binding domain of spike glycoprotein.

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.